一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> BMC Biology >>article
BMC Biology

BMC Biology

IF: 4.5
Download PDF

ARv7 promotes the escape of prostate cancer cells from androgen deprivation therapy-induced senescence by mediating the SKP2/p27 axis

Published:28 February 2025 DOI: 10.1186/s12915-025-02172-4 PMID: 40022149
Dian Zhuang,?Jinsong Kang,?Haoge Luo,?Yu Tian,?Xiaoping Liu,?Chen Shao

Abstract

Background: Androgen deprivation therapy (ADT) induces cellular senescence and tumor stasis, thus serving as the standard treatment for prostate cancer (PCa). However, continuous suppression of canonical androgen receptor signaling actually leads to the switch from androgen-responsive growth to androgen-independent growth, contributing to "escape" from this ADT-induced senescence (AIS) and, subsequently, the development of castration-resistant prostate cancer (CRPC). Unfortunately, the mechanism underlying this phenomenon remains elusive.

Results: In this study, we demonstrated that androgen receptor splicing variant 7 (ARv7), a dominant factor mediating abnormal AR signaling and ADT resistance, is closely associated with outgrowth from AIS of PCa cells. Mechanistically, ARv7 binds to the promoter of SKP2, activating its transcription, and then promotes the proteasomal degradation of the cell cycle regulator p27 and G1/S transition. In addition, we applied bioinformatic and in vitro analyses to show that SKP2 expression level is dramatically inhibited upon ADT, but its reactivation is one key step during the establishment of CRPC. Finally, we also demonstrated that SKP2 inhibitor treatment can significantly inhibit the growth of androgen-independent cell lines and enhance the efficacy of ADT.

Conclusions: Our work reveals a novel role of ARv7 in regulating AIS and suggests that targeting the ARv7/SKP2/p27 axis could be a potential strategy to delay disease progression to the CRPC state during prolonged ADT.

Substances (12)

Materials
Procduct Name CAS Molecular Formula Supplier Price
Enzalutamide 915087-33-1 C21H16F4N4O2S 606 suppliers $5.00-$17482.50
Enzalutamide 915087-33-1 C21H16F4N4O2S 606 suppliers $5.00-$17482.50
Enzalutamide 915087-33-1 C21H16F4N4O2S 606 suppliers $5.00-$17482.50
Enzalutamide 915087-33-1 C21H16F4N4O2S 606 suppliers $5.00-$17482.50
MG-132 133407-82-6 C26H41N3O5 427 suppliers $11.00-$9807.90
MG-132 133407-82-6 C26H41N3O5 427 suppliers $11.00-$9807.90
MG-132 133407-82-6 C26H41N3O5 427 suppliers $11.00-$9807.90
MG-132 133407-82-6 C26H41N3O5 427 suppliers $11.00-$9807.90
Skp2 Inhibitor C1 432001-69-9 C18H13BrN2O4S2 101 suppliers $18.00-$2841.00
Skp2 Inhibitor C1 432001-69-9 C18H13BrN2O4S2 101 suppliers $18.00-$2841.00

Similar articles

唐山市| 玉树县| 桐乡市| 五华县| 特克斯县| 海原县| 浑源县| 壤塘县| 沽源县| 公安县| 塔河县| 城固县| 乐安县| 昆山市| 淮滨县| 闸北区| 紫阳县| 三明市| 桐梓县| 临猗县| 阿拉善右旗| 洪泽县| 南漳县| 清新县| 麦盖提县| 吴江市| 武义县| 桂平市| 康保县| 长治县| 红原县| 罗源县| 金沙县| 青神县| 醴陵市| 江都市| 根河市| 五家渠市| 安新县| 衡东县| 秦安县|